Key Takeaways
- • MusclePharm, a California-based protein powder manufacturer, faces a court hearing Friday against Boston-based hedge fund White Winston Capital, which holds a 19.9% stake and seeks to block a shareholder-dilutive equity conversion deal.
- • CEO Ryan Drexler proposes converting an $18 million personal loan into equity; White Winston claims this enriches Drexler while squeezing existing shareholders, prompting legal action described in a 209-page opposition motion.
- • MusclePharm has generated annual losses since its 2006 inception, with revenue declining 25% over the past three years, weakened by costly endorsement deals with Tiger Woods, Colin Kaepernick, and Arnold Schwarzenegger.
- • Drexler assumed control in 2015 as the company's financial position deteriorated, subsequently eliminating premium endorsement contracts through litigation and pivoting toward organic sales growth.
- • MusclePharm counters that White Winston's lawsuit constitutes extortion, arguing the hedge fund's legal maneuvers—not the proposed deal—are the primary threat to shareholder value.
Summary
MusclePharm Corporation, a struggling protein supplement manufacturer, will defend its strategic financing proposal in court this Friday against White Winston Capital, a Boston-based hedge fund controlling 19.9% of the company's equity. The dispute centers on CEO Ryan Drexler's plan to convert an $18 million loan he extended to the company into equity ownership. White Winston, led by Todd Enright, contends the conversion disproportionately benefits Drexler while diluting the stakes of existing shareholders. The hedge fund filed suit seeking to block the transaction, asserting in court documents that the arrangement enriches management at shareholders' expense.
MusclePharm's financial trajectory has deteriorated substantially since its founding in 2006. The company has reported losses in every fiscal year of operation and has experienced a 25% decline in revenue over the preceding three-year period. The organization's financial strain intensified during the early 2010s when management pursued expensive endorsement agreements with celebrity athletes including Tiger Woods, Colin Kaepernick, and Arnold Schwarzenegger. While initially effective as a marketing strategy, the rising costs of these deals ultimately became unsustainable given the company's revenue base.
Drexler acquired controlling interest in MusclePharm in 2015 as the organization faced acute financial distress. In interviews, Drexler acknowledged that the endorsement strategy, though initially successful, became untenable when payment obligations exceeded the scale of company operations. Following his arrival, he systematically terminated the premium sponsorship contracts—several of which required costly litigation settlements—and refocused the business on organic revenue growth and operational efficiency.
MusclePharm has mounted an aggressive defense against White Winston's legal challenge, filing a 209-page opposition motion characterizing the hedge fund's lawsuit as a bad-faith extortion scheme. Company counsel argues that White Winston's litigation itself constitutes the genuine threat to shareholder interests, rather than the proposed equity conversion. The company claims White Winston fabricated allegations "out of whole cloth" in an attempt to coerce management into paying the hedge fund to withdraw its objection.
The Friday hearing will determine whether Drexler's proposed equity conversion proceeds or faces judicial blockade. The outcome carries implications for capital structure negotiations between activist investors and distressed operating companies, particularly in sectors where brand-dependent business models remain vulnerable to shifting endorsement economics.
MusclePharm's financial trajectory has deteriorated substantially since its founding in 2006. The company has reported losses in every fiscal year of operation and has experienced a 25% decline in revenue over the preceding three-year period. The organization's financial strain intensified during the early 2010s when management pursued expensive endorsement agreements with celebrity athletes including Tiger Woods, Colin Kaepernick, and Arnold Schwarzenegger. While initially effective as a marketing strategy, the rising costs of these deals ultimately became unsustainable given the company's revenue base.
Drexler acquired controlling interest in MusclePharm in 2015 as the organization faced acute financial distress. In interviews, Drexler acknowledged that the endorsement strategy, though initially successful, became untenable when payment obligations exceeded the scale of company operations. Following his arrival, he systematically terminated the premium sponsorship contracts—several of which required costly litigation settlements—and refocused the business on organic revenue growth and operational efficiency.
MusclePharm has mounted an aggressive defense against White Winston's legal challenge, filing a 209-page opposition motion characterizing the hedge fund's lawsuit as a bad-faith extortion scheme. Company counsel argues that White Winston's litigation itself constitutes the genuine threat to shareholder interests, rather than the proposed equity conversion. The company claims White Winston fabricated allegations "out of whole cloth" in an attempt to coerce management into paying the hedge fund to withdraw its objection.
The Friday hearing will determine whether Drexler's proposed equity conversion proceeds or faces judicial blockade. The outcome carries implications for capital structure negotiations between activist investors and distressed operating companies, particularly in sectors where brand-dependent business models remain vulnerable to shifting endorsement economics.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.